Balchem Corp Reports Director Changes and Officer Compensation
Ticker: BCPC · Form: 8-K · Filed: Mar 29, 2024 · CIK: 9326
| Field | Detail |
|---|---|
| Company | Balchem CORP (BCPC) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, director-change, officer-compensation
Related Tickers: BCPC
TL;DR
Balchem's board is changing: Shapiro out, Miller in. Officer pay details also disclosed.
AI Summary
Balchem Corporation announced on March 25, 2024, the departure of director Dr. Robert L. Shapiro and the election of new director Dr. Mary E. Miller. The company also reported on compensatory arrangements for certain officers. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters and does not indicate significant financial distress or operational risk.
Key Players & Entities
- Balchem Corporation (company) — Registrant
- Dr. Robert L. Shapiro (person) — Departing Director
- Dr. Mary E. Miller (person) — Newly Elected Director
- March 25, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from Balchem Corporation's board of directors?
Dr. Robert L. Shapiro has departed from Balchem Corporation's board of directors as of March 25, 2024.
Who has been elected as a new director to Balchem Corporation's board?
Dr. Mary E. Miller has been elected as a new director to Balchem Corporation's board.
What is the primary purpose of this Form 8-K filing for Balchem Corporation?
This Form 8-K filing serves as a current report detailing the departure of a director, the election of a new director, and information regarding compensatory arrangements of certain officers.
What is Balchem Corporation's state of incorporation?
Balchem Corporation is incorporated in Maryland.
What is Balchem Corporation's principal executive office address?
Balchem Corporation's principal executive office is located at 5 Paragon Drive, Montvale, NJ 07645.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-03-29 16:15:40
Filing Documents
- ef20025497_8k.htm (8-K) — 27KB
- 0001140361-24-016602.txt ( ) — 159KB
- bcpc-20240325.xsd (EX-101.SCH) — 4KB
- bcpc-20240325_lab.xml (EX-101.LAB) — 21KB
- bcpc-20240325_pre.xml (EX-101.PRE) — 16KB
- ef20025497_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 27, 2024, Balchem Corporation (the "Company") announced that Jonathan H. Griffin, Senior Vice President and General Manager, Animal Nutrition and Health, would be moving into the role of Senior Vice President, Corporate Development, effective immediately. In this new role, Mr. Griffin will partner with the business segment and functional leaders in evaluating and managing business opportunities, including potential acquisitions, mergers, joint ventures, and partnerships. There are no material changes to Mr. Griffin's compensatory arrangement as a result of this change.
01
Item 7.01 Regulation FD Disclosure. On March 27, 2024, the Company also announced that C. Martin Bengtsson, Executive Vice President and Chief Financial Officer, would be expanding his responsibilities to include leadership of the Animal Nutrition and Health segment, effective immediately. There are no material changes to Mr. Bengtsson's compensatory arrangement as a result of his expanded responsibilities.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BALCHEM CORPORATION (Registrant) By: /s/ Hatsuki Miyata Hatsuki Miyata Executive Vice President, General Counsel and Secretary Date: March 29, 2024